Low insulin sensitivity and a selective loss of acute insulin release identify those individuals at the highest risk of developing type 2 diabetes. Normally, the rapid release of insulin after the ingestion of a meal is critical for post-prandial glucose regulation as first-phase insulin modulates suppression of endogenous glucose production and, therefore, limits meal-related plasma glucose excursions. The loss of first-phase insulin secretion contributes to the development of glucose intolerance. Indeed, postprandial hyperglycaemia represents the first and more evident perturbation of glucose homeostasis in about 60% of newly diagnosed type 2 diabetic patients. In these individuals, restoration of first-phase insulin secretion may result in more efficient inhibition of hepatic glucose production and improved glucose tolerance. In the light of these considerations, therapeutic intervention either alone or in combination with improvement of insulin resistance should be considered early in the course of the disease to prevent excessively rapid deterioration of glycaemic control.
Del Prato S., Maran A., Beck-Nielsen H.The plurimetabolic syndrome in the European Population: the experience of the European Group on Insulin Resistance (EGIR). Insulin Resistance, Metabolic Diseases and Diabetic Complications. In: Crepaldi G, Tiengo A, Del Prato S. eds. Excerpta Medica. International Congress Series 1177, Internal Medicine. Elsevier, Amsterdam, 1999:25-30.
2.
Haffner SM, Miettinen H., Gaskill SP, Stern M.Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. Diabetologia1996 ;39:1201-07.
3.
Bonora E., Formentini G., Calcaterra F. et al. HOMA-Estimated Insulin Resistance is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects: Prospective data from the Verona Diabetes Complications Study. Diabetes Care2002;25:1135-41.
4.
Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab1976;42:222-9.
5.
Del Prato S., Ferrannini E., DeFronzo RAEvaluation of Insulin Sensitivity in Man. In: Methods in Diabetes Research, Vol. II, Clarke WL, Larner J.Pohl SL eds, J. Wiley & Sons, 1986:35-76.
6.
Toffolo G., Bergman RN, Finegood DT, Bowden CR, Cobelli C.Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. Diabetes1980;29:979-90.
7.
Yoneda H., Ikegami H., Yamamoto et al. Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance . Diabetes Care1992;15:1517-21.
8.
Cretti A., Lehtovirta M., Bonora E. et al. Assessment of beta-cell function secretion. Eur J Clin Invest2001;31:405-16. during the oral glucose tolerance test by a minimal model of insulin secretion, Eur J Clin Invest2001;31:405-16
9.
Mari A.Mathematical modeling in glucose metabolism and insulin secretion. Curr Opin Clin Nutr Metab Care2002;5:495-501.
10.
Holman RRAssessing the potential for alpha-glucosidase inhibitors in prediabetic states . Diabetes Res Clin Pract1998;40(suppl):S21-S25.
11.
Larsson H., Ahren B.Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagons secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care2000;23:650-7.
12.
Haffner SM, Mykkanen L., Festa A., Burke JP, Stern MPInsulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation2000;101:975-80.
13.
Lundgren H. , Bengtsson C., Blohmè G., Lapidus L., Waldeström J.Fasting serum insulin concentration and early insulin response as risk determinants for developing diabetes. Diabet Med1990;7:407-13.
14.
Kosaka K., Kuzuya T., Hagura R., Yoshinaga H.Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus . Diabet Med1996;13:S109-S119.
15.
Hanson RL, Pratley RE, Bogardus C. et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol2000;151:190-8.
16.
Del Prato S. , Marchetti P., Bonadonna RCPhasic insulin release and metabolic regulation in type 2 diabetes. Diabetes2002;51(suppl 1):S109-S116.
17.
Weyer C., Bogardus C., Mott DM, Pratley REThe natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest1999;104:787-94.
18.
Weyer C., Tataranni PA, Bogardus C., Prately REInsulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of Type 2 diabetes development . Diabetes Care2001;24:89-94.
19.
Ferrannini E., Gastaldelli A., Miyazaki Y., Matsuda M., Mari A., DeFronzo RABeta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab2005;90:493-500.
20.
Gastaldelli A., Ferrannini E., Miyazaki Y., Matsuda M., DeFronzo RASan Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study . Diabetologia2004;47:31-9.
21.
Bruce DG, Storlien LH, Furler SM, Chisholm DJCephalic phase metabolic responses in normal weight adults. Metabolism1987;36:721-5.
22.
Mitrakou A. , Kelley D., Mokan M. et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance . N Engl J Med1992;326:22-9.
23.
Cherrington AD, Sindelar D., Edgerton D., Steiner K., McGuinness OPPhysiological consequences of phasic insulin release in the normal animal. Diabetes2002 ;51(suppl 1):S103-S108.
24.
Luzi L., DeFronzo RAEffect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol1989;257:E241-E246.
25.
Calles-Escandon J., Robbins DCLoss of early phase of insulin release in humans impairs gucose tolerance and blunts thermic effect of glucose. Diabetes1987;36:1167-72.
26.
Basu A., Alzaid A., Dinneen S., Caumo A., Cobelli C., Rizza RAEffects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest1986;97:2351-61.
27.
Sartor G., Schersten B., Carlstrom S., Melander A., Norden A., Persson G.Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes1980;29:41-9.
28.
Knowler WC, Barrett-Connor E., Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002;346:393-403.
29.
Tuomilehto J., Lindstrom J., Eriksson JG et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343-50
30.
Del Prato S. , Leonetti F., Simonson DC, Sheean P., Matsuda M., DeFronzo RAEffect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia1994;37:1025-35.
31.
Kashyap S., Belfort R., Gastaldelli A. et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes2003;52:2461-74.
32.
Bruce DG, Chisholm DJ, Storlien LH, Kraegen EWPhysiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes1988;37:736-44.
33.
Bruttomesso D., Pianta A., Mari A. et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients . Diabetes1999;48:99-105.
34.
Hosker JP, Rudenski AS, Burnett MA et al. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism1989;38:767-72.
35.
Juhl CB, Porksen N., Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes2001;50:1778-84.
Holst JJ, Gromada J.Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab2004;287:E199-E206.
38.
Rachman J.Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes. Diabet Med2004 ;21 (suppl 1):18-20.
39.
Wiedeman PE , Trevillyan JMDipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs2003;4:412-20.
